Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Opthea Limited Sponsored ADR ( (OPT) ).
Opthea Limited has announced its upcoming Annual General Meeting, scheduled for November 11, 2025, which will be held virtually. Key agenda items include the re-election of directors Dr. Jeremy Levin and Ms. Kathy Connell, the adoption of the remuneration report, and the issuance of options under the company’s incentive plans. These resolutions are expected to influence Opthea’s governance and compensation structure, potentially impacting shareholder value and company strategy.
The most recent analyst rating on (OPT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Opthea Limited Sponsored ADR stock, see the OPT Stock Forecast page.
Spark’s Take on OPT Stock
According to Spark, TipRanks’ AI Analyst, OPT is a Underperform.
Opthea Limited’s stock is currently rated low due to significant financial challenges, including persistent losses, high leverage, and poor cash flow management. The technical analysis indicates a bearish trend with no immediate recovery signals. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, suggesting limited appeal to investors seeking growth or income. The stock’s high beta adds to the risk profile, emphasizing the need for strategic improvements to enhance financial performance.
To see Spark’s full report on OPT stock, click here.
More about Opthea Limited Sponsored ADR
Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for eye diseases. The company is primarily engaged in advancing treatments for conditions such as wet age-related macular degeneration and diabetic macular edema, aiming to address significant unmet needs in ophthalmology.
Technical Sentiment Signal: Sell
Current Market Cap: $485.2M
For an in-depth examination of OPT stock, go to TipRanks’ Overview page.